Flibanserin

Independent reference data for Flibanserin (CAS 167933-07-5), compiled from public chemistry databases.

Registry identifiers across databases

Computed descriptors

Documented uses on record

Preparation: M. Turconi et al., European Patent Office patent 526434; G. Bietti et al., USA patent 5576318 (1993, 1996 both to Boehringer Ingelheim).Flibansetrin is indicated for the treatment of women less than 65 years of age with acquired, generalized hypoactive sexual desire disorder (HSDD) as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is not due to: - A co-existing medical or psychiatric condition, - Problems within the relationship, or - The effects of a medication or other drug substance. In Canada, it is approved for the same indication but in women less than 60 years of age.

Synonyms and trade names

Flibanserin; 167933-07-5; Bimt-17; Addyi; Bimt 17; Ectris; Girosa; BIMT 17 BS; BIMT-17-BS; flibanserina; Flibanserine; 37JK4STR6Z; 1,3-Dihydro-1-(2-(4-(3-(trifluoromethyl)phenyl)-1-piperazinyl)ethyl)-2H-benzimidazol-2-one; 3-[2-[4-[3-(trifluoromethyl)phenyl]piperazin-1-yl]ethyl]-1H-benzimidazol-2-one; Female Viagra (Street Name); Female Viagra [Street Name]

GHS hazard classification

Reported hazard statements	H301 (92.7%), H315 (95.1%), H319 (95.1%), H335 (92.7%)

H301 (92.7%): Toxic if swallowed [Danger Acute toxicity, oral]

H315 (95.1%): Causes skin irritation [Warning Skin corrosion/irritation]

What the public record says

Flibanserin · CAS 167933-07-5 · C20H21F3N4O. UNII 37JK4STR6Z.

Physical description and handling notes

Source: PubChem / Wikidata; the batch COA governs where values differ.